177 related articles for article (PubMed ID: 23879408)
21. Induction Therapies in Live Donor Kidney Transplantation on Tacrolimus and Mycophenolate With or Without Steroid Maintenance.
Tanriover B; Zhang S; MacConmara M; Gao A; Sandikci B; Ayvaci MU; Mete M; Tsapepas D; Rajora N; Mohan P; Lakhia R; Lu CY; Vazquez M
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1041-9. PubMed ID: 25979971
[TBL] [Abstract][Full Text] [Related]
22. Optimizing tacrolimus therapy in the maintenance of renal allografts: 12-month results.
Bolin P; Shihab FS; Mulloy L; Henning AK; Gao J; Bartucci M; Holman J; First MR;
Transplantation; 2008 Jul; 86(1):88-95. PubMed ID: 18622283
[TBL] [Abstract][Full Text] [Related]
23. Conversion of twice-daily to once-daily tacrolimus is safe in stable adult living donor liver transplant recipients.
Kim SH; Lee SD; Kim YK; Park SJ
Hepatobiliary Pancreat Dis Int; 2015 Aug; 14(4):374-9. PubMed ID: 26256081
[TBL] [Abstract][Full Text] [Related]
24. Risk Factors Affecting Graft and Patient Survivals After Transplantation From Deceased Donors in a Developing Country: A Single-Center Experience.
Ayar Y; Ersoy A; Ocakoglu G; Yildiz A; Oruc A; Soyak H; Calapkulu M; Sahin AB; Topal NB; Okeer E; Coskun B; Kaygisiz O; Kordan Y; Vuruskan H
Transplant Proc; 2017 Mar; 49(2):270-277. PubMed ID: 28219583
[TBL] [Abstract][Full Text] [Related]
25. Tacrolimus trough-level variability predicts long-term allograft survival following kidney transplantation.
O'Regan JA; Canney M; Connaughton DM; O'Kelly P; Williams Y; Collier G; deFreitas DG; O'Seaghdha CM; Conlon PJ
J Nephrol; 2016 Apr; 29(2):269-276. PubMed ID: 26374111
[TBL] [Abstract][Full Text] [Related]
26. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
Gallon LG; Winoto J; Chhabra D; Parker MA; Leventhal JR; Kaufman DB
Transplantation; 2007 May; 83(10):1324-9. PubMed ID: 17519781
[TBL] [Abstract][Full Text] [Related]
27. Sirolimus vs mycophenolate moftile in Tacrolimus based therapy following induction with Antithymocyte globulin promotes regulatory T cell expansion and inhibits RORγt and T-bet expression in kidney transplantation.
Jamali S; Sarafnejad A; Ahmadpoor P; Nafar M; Karimi M; Eteghadi A; Yekaninejad MS; Amirzargar AA
Hum Immunol; 2019 Sep; 80(9):739-747. PubMed ID: 30597187
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of the Combination of Everolimus and Tacrolimus With High Dosage of Mizoribine for Living Donor-Related Kidney Transplantation.
Yoshimura N; Nakao T; Nakamura T; Harada S; Koshino K; Suzuki T; Ito T; Nobori S; Ushigome H
Transplant Proc; 2016 Apr; 48(3):786-9. PubMed ID: 27234736
[TBL] [Abstract][Full Text] [Related]
29. Tacrolimus variability is associated with de novo donor-specific antibody development in pediatric renal transplant recipients.
Solomon S; Colovai A; Del Rio M; Hayde N
Pediatr Nephrol; 2020 Feb; 35(2):261-270. PubMed ID: 31732803
[TBL] [Abstract][Full Text] [Related]
30. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
31. Tacrolimus trough levels and level-to-dose ratio in stable renal transplant patients converted to a once-daily regimen.
Meçule A; Tinti F; Poli L; Bachetoni A; Umbro I; Nofroni I; Lai Q; Pretagostini R; Berloco PB; Mitterhofer AP
Transplant Proc; 2011 May; 43(4):1024-7. PubMed ID: 21620042
[TBL] [Abstract][Full Text] [Related]
32. Tacrolimus Concentration/Dose Ratio is Associated with Renal Function After Liver Transplantation.
Thölking G; Siats L; Fortmann C; Koch R; Hüsing A; Cicinnati VR; Gerth HU; Wolters HH; Anthoni C; Pavenstädt H; Suwelack B; Schmidt HH; Kabar I
Ann Transplant; 2016 Mar; 21():167-79. PubMed ID: 27003330
[TBL] [Abstract][Full Text] [Related]
33. Higher tacrolimus trough levels on days 2-5 post-renal transplant are associated with reduced rates of acute rejection.
O'Seaghdha CM; McQuillan R; Moran AM; Lavin P; Dorman A; O'Kelly P; Mohan DM; Little P; Hickey DP; Conlon PJ
Clin Transplant; 2009; 23(4):462-8. PubMed ID: 19681975
[TBL] [Abstract][Full Text] [Related]
34. Immunosuppression for delayed or slow graft function in primary cadaveric renal transplantation: use of low dose tacrolimus therapy with post-operative administration of anti-CD25 monoclonal antibody.
Gonwa TA; Mai ML; Smith LB; Levy MF; Goldstein RM; Klintmalm GB
Clin Transplant; 2002 Apr; 16(2):144-9. PubMed ID: 11966785
[TBL] [Abstract][Full Text] [Related]
35. Assessment of rejection risk following subtherapeutic calcineurin inhibitor levels after pediatric heart transplantation.
Kerr SM; Jorgensen NW; Hong BJ; Friedland-Little JM; Albers EL; Newland DM; Law YM; Kemna MS
Pediatr Transplant; 2020 Feb; 24(1):e13616. PubMed ID: 31820529
[TBL] [Abstract][Full Text] [Related]
36. Early calcineurin-inhibitor to belatacept conversion in steroid-free kidney transplant recipients.
Tawhari I; Hallak P; Bin S; Yamani F; Safar-Boueri M; Irshad A; Leventhal J; Ansari MJ; Cravedi P; Gallon L
Front Immunol; 2022; 13():1096881. PubMed ID: 36601111
[TBL] [Abstract][Full Text] [Related]
37. Intrapatient Variability in Tacrolimus Trough Levels Over 2 Years Affects Long-Term Allograft Outcomes of Kidney Transplantation.
Park Y; Lee H; Eum SH; Kim HD; Ko EJ; Yang CW; Chung BH
Front Immunol; 2021; 12():746013. PubMed ID: 34659243
[TBL] [Abstract][Full Text] [Related]
38. Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure.
Sapir-Pichhadze R; Wang Y; Famure O; Li Y; Kim SJ
Kidney Int; 2014 Jun; 85(6):1404-11. PubMed ID: 24336032
[TBL] [Abstract][Full Text] [Related]
39. Non-linear Relationship between Tacrolimus Blood Concentration and Acute Rejection After Kidney Transplantation: A Systematic Review and Dose-Response Meta-Analysis of Cohort Studies.
Yin S; Song T; Li X; Xu H; Zhang X; Jiang Y; Lin T
Curr Pharm Des; 2019; 25(21):2394-2403. PubMed ID: 31333109
[TBL] [Abstract][Full Text] [Related]
40. Conversion from tacrolimus-mycophenolate mofetil to tacrolimus-mTOR immunosuppression after kidney-pancreas transplantation reduces the incidence of both BK and CMV viremia.
Knight RJ; Graviss EA; Nguyen DT; Kuten SA; Patel SJ; Gaber L; Gaber AO
Clin Transplant; 2018 Jun; 32(6):e13265. PubMed ID: 29676018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
